Cryo-Cell International Inc (CCEL)
XASE:CCEL
Want to see CCEL full AI Analyst Report?
CCEL Stock Chart & Stats
$4.09
-$0.37(-4.74%)
At close: 4:00 PM EST
$4.09
-$0.37(-4.74%)
Day’s Range― - ―
52-Week Range$2.72 - $6.35
Previous CloseN/A
Volume3.40K
Average Volume (3M)4.07K
Market Cap
$32.62M
Enterprise Value$30.58M
Total Cash (Recent Filing)$2.90M
Total Debt (Recent Filing)$2.40M
Price to Earnings (P/E)―
Beta>-0.01
Next Earnings
Jul 09, 2026Next Dividend Ex-DateN/A
Dividend Yield11.14%
Share Statistics
EPS (TTM)-0.32
Shares Outstanding8,055,150
10 Day Avg. Volume4,683
30 Day Avg. Volume4,066
Financial Highlights & Ratios
PEG Ratio0.02
Price to Book (P/B)-1.73
Price to Sales (P/S)1.02
P/FCF Ratio6.12
Enterprise Value/Market Cap0.94
Enterprise Value/Revenue0.98
Enterprise Value/Gross Profit1.26
Enterprise Value/Ebitda51.87
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusHold
Number of Analyst Covering1
EPS Forecast (FY)0.08
Revenue Forecast (FY)$30.30M
Bulls Say, Bears Say
Bulls Say
Strong Gross MarginsSustained mid-70% gross margins indicate durable unit economics for cord blood/tissue processing and storage. High gross margins support long-term cash generation from each customer even if revenue growth is slow, enabling reinvestment in lab capabilities and margin resilience over cycles.
Positive Operating Cash FlowConsistent positive operating cash flow across periods suggests the business converts revenue to cash despite reported net losses. Reliable cash generation reduces near-term dependence on external financing and supports funding for operations, compliance remediation, and capital needs over the medium term.
Reduced Debt LevelsMeaningful reduction in debt lowers interest burden and improves solvency headroom, giving management more flexibility to address strategic priorities. Lower leverage helps preserve cash flow for operations and reduces refinancing risk while the company works to repair equity deficits and restore stability.
Bears Say
Negative Stockholders' EquityA persistent stockholders' deficit materially weakens the balance sheet, limiting financial flexibility and increasing funding and covenant risks. Negative equity is a structural constraint that can restrict access to credit, raise borrowing costs, and force dilutive remedies or asset sales to restore solvency.
Revenue Decline And Ongoing LossesFlat-to-declining revenue combined with sustained net losses undermines the recurring storage revenue model and reduces margin leverage over time. Without durable revenue growth, high gross margins cannot translate to operating profitability, making long-term recovery and sustainable cash flow uncertain.
NYSE American Listing Compliance RiskA formal non-compliance notice creates structural risk: potential delisting or mandated remediation can force management to prioritize short-term balance-sheet fixes, including dilutive financing. The process can limit strategic options and investor access for an extended period if not resolved.
Cryo-Cell International News
CCEL FAQ
What was Cryo-Cell International Inc’s price range in the past 12 months?
Cryo-Cell International Inc lowest stock price was $2.72 and its highest was $6.35 in the past 12 months.
What is Cryo-Cell International Inc’s market cap?
Cryo-Cell International Inc’s market cap is $32.62M.
When is Cryo-Cell International Inc’s upcoming earnings report date?
Cryo-Cell International Inc’s upcoming earnings report date is Jul 09, 2026 which is in 20 days.
How were Cryo-Cell International Inc’s earnings last quarter?
Cryo-Cell International Inc released its earnings results on Apr 14, 2026. The company reported $0.01 earnings per share for the quarter, beating the consensus estimate of -$0.02 by $0.03.
Is Cryo-Cell International Inc overvalued?
According to Wall Street analysts Cryo-Cell International Inc’s price is currently Overvalued.
Does Cryo-Cell International Inc pay dividends?
Cryo-Cell International Inc pays a Quarterly dividend of $0.15 which represents an annual dividend yield of 11.14%. See more information on Cryo-Cell International Inc dividends here
What is Cryo-Cell International Inc’s EPS estimate?
Cryo-Cell International Inc’s EPS estimate is 0.
How many shares outstanding does Cryo-Cell International Inc have?
Cryo-Cell International Inc has 8,055,150 shares outstanding.
What happened to Cryo-Cell International Inc’s price movement after its last earnings report?
Cryo-Cell International Inc reported an EPS of $0.01 in its last earnings report, beating expectations of -$0.02. Following the earnings report the stock price went up 1.09%.
Which hedge fund is a major shareholder of Cryo-Cell International Inc?
Currently, no hedge funds are holding shares in CCEL
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Cryo-Cell International Inc
Cryo-Cell International, Inc. specializes in the cryogenic preservation and processing of cells, primarily focusing on collecting and storing umbilical cord blood stem cells for personal family use. The company also offers a cord tissue banking service, securing a section of the umbilical cord itself. This tissue is a valuable source of mesenchymal stem cells, which are utilized in regenerative medicine to address a range of conditions, including various heart and kidney diseases, Amyotrophic Lateral Sclerosis (ALS), wound healing, and autoimmune disorders. Furthermore, Cryo-Cell manufactures and distributes its proprietary PrepaCyte CB processing system, specifically designed for umbilical cord blood stem cells. With a substantial global presence, the company safeguards approximately 500,000 units of cord blood and cord tissue stem cells. Their marketing efforts include direct outreach to expectant parents, alongside disseminating information through a network of healthcare professionals such as obstetricians, pediatricians, childbirth educators, and certified nurse-midwives. Established in 1989, Cryo-Cell International, Inc. is headquartered in Oldsmar, Florida.
CCEL Stock 12 Month Forecast
Average Price Target
―Technical Analysis
American Shared Hospital Services
―
Concord Medical Services
―
―
DocGo
―
P3 Health Partners
―
Ownership Overview
35.79% Insiders
2.57% Mutual Funds
2.05% Other Institutional Investors
57.69% Public Companies and
Individual Investors
Options Prices
Currently, No data available
---